{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:55:07Z","timestamp":1787003707005,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The replacement of animal-derived components from cell culture protocols is essential for the development of human-compatible and clinically translatable systems. Fetal bovine serum (FBS) is still widely used for cell expansion, although its xenogeneic origin and batch variability limit regulatory compliance. In this study, human platelet lysate (hPL) and human serum (HS) were assessed as low-serum (2%) alternatives to FBS during the subculture phase of bone marrow-derived mesenchymal stromal cells (BM-MSC) prior to keratocyte differentiation for corneal tissue engineering. BM-MSC were gradually adapted over four days to 2% FBS, hPL, or HS, maintained for seven days, and then transferred to serum-free keratocyte differentiation medium for 14 days in either two-dimensional (2D) or three-dimensional (3D) cultures in 30 wt% riboflavin-arginine-triggered gelatin methacryloyl (RA-GelMA) hydrogels crosslinked under visible blue light. To demonstrate the applicability of this approach in corneal tissue engineering, differentiation was evaluated by immunofluorescence and quantitative PCR in 2D cultures, and by immunofluorescence in 3D cultures. Both hPL and HS maintained metabolic activity, supported keratocyte-associated marker expression, and suppressed \u03b1-SMA, performing comparably to FBS, thereby supporting their use as clinically compliant, human-derived alternatives for xeno-reduced corneal biomanufacturing.<\/jats:p>","DOI":"10.1038\/s41598-026-58401-5","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:53:19Z","timestamp":1781729599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toward clinically relevant automated corneal biomanufacturing with human-derived FBS alternatives"],"prefix":"10.1038","volume":"16","author":[{"given":"Alexandre","family":"Taoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia S.","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Thaden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Wisbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Fuest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Dehli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela F.","family":"Duarte Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"58401_CR1","doi-asserted-by":"publisher","unstructured":"Wang, E. Y. et al. Global trends in blindness and vision impairment resulting from corneal opacity 1984\u20132020: a meta-analysis. Ophthalmology 130, 863\u2013871. https:\/\/doi.org\/10.1016\/j.ophtha.2023.03.012 (2023).","DOI":"10.1016\/j.ophtha.2023.03.012"},{"key":"58401_CR2","doi-asserted-by":"publisher","unstructured":"Lamm, V., Hara, H., Mammen, A., Dhaliwal, D. & Cooper, D. K. Corneal blindness and xenotransplantation. Xenotransplantation 21, 99\u2013114. https:\/\/doi.org\/10.1111\/xen.12082 (2014).","DOI":"10.1111\/xen.12082"},{"key":"58401_CR3","doi-asserted-by":"publisher","first-page":"707242","DOI":"10.3389\/fmed.2021.707242","volume":"8","author":"A Song","year":"2021","unstructured":"Song, A. et al. Post-keratoplasty infectious keratitis: epidemiology, risk factors, management, and outcomes. Front. Med. (Lausanne). 8, 707242. https:\/\/doi.org\/10.3389\/fmed.2021.707242 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"58401_CR4","doi-asserted-by":"publisher","unstructured":"Alio, J. L., Montesel, A., El Sayyad, F., Barraquer, R. I. & Arnalich-Montiel, F. Corneal graft failure: an update. Br. J. Ophthalmol. 105 (8), 1049\u20131058. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316705 (2021).","DOI":"10.1136\/bjophthalmol-2020-316705"},{"key":"58401_CR5","doi-asserted-by":"publisher","unstructured":"Gain, P. et al. Global survey of corneal transplantation and eye banking. JAMA Ophthalmol. 134 (2), 167\u2013173. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.4776 (2016).","DOI":"10.1001\/jamaophthalmol.2015.4776"},{"key":"58401_CR6","doi-asserted-by":"publisher","unstructured":"AlMutlak, M., Li, J. Y., Helayel, H. B. & Fairaq, R. Future of corneal donation and transplantation: insights from the COVID-19 pandemic. Cornea 40, 274\u2013276. https:\/\/doi.org\/10.1097\/ICO.0000000000002538 (2021).","DOI":"10.1097\/ICO.0000000000002538"},{"key":"58401_CR7","doi-asserted-by":"publisher","unstructured":"Duarte Campos, D. F. et al. Corneal bioprinting utilizing collagen-based bioinks and primary human keratocytes. J. Biomed. Mater. Res. A. 107 (9), 1945\u20131953. https:\/\/doi.org\/10.1002\/jbm.a.36702 (2019).","DOI":"10.1002\/jbm.a.36702"},{"key":"58401_CR8","doi-asserted-by":"publisher","unstructured":"Balters, L. & Reichl, S. 3D bioprinting of corneal models: a review of the current state and future outlook, J. Tissue Eng. 14, 20417314231197793. https:\/\/doi.org\/10.1177\/20417314231197793 (2023).","DOI":"10.1177\/20417314231197793"},{"key":"58401_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fbioe.2019.00135","volume":"7","author":"M Mobaraki","year":"2019","unstructured":"Mobaraki, M. et al. Corneal repair and regeneration: current concepts and future directions. Front. Bioeng. Biotechnol. 7, 135. https:\/\/doi.org\/10.3389\/fbioe.2019.00135 (2019).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"58401_CR10","doi-asserted-by":"publisher","unstructured":"Matthyssen, S., Van den Bogerd, B., Dhubhghaill, S. N., Koppen, C. & Zakaria, N. Corneal regeneration: a review of stromal replacements. Acta Biomater. 69, 31\u201341. https:\/\/doi.org\/10.1016\/j.actbio.2018.01.023 (2018).","DOI":"10.1016\/j.actbio.2018.01.023"},{"issue":"11","key":"58401_CR11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/stcltm\/szad058","volume":"12","author":"C Bonnet","year":"2023","unstructured":"Bonnet, C., Gonz\u00e1lez, S. & Deng, S. X. Ocular surface regeneration by limbal stem cells therapies: state of the art, challenges, and perspectives. Stem Cells Transl. Med. 12 (11), 714\u2013719. https:\/\/doi.org\/10.1093\/stcltm\/szad058 (2023).","journal-title":"Stem Cells Transl. Med."},{"key":"58401_CR12","doi-asserted-by":"crossref","unstructured":"Gu\u00e9rin, L. P. et al. The Human Tissue-Engineered Cornea (hTEC): recent progress. Int. J. Mol. Sci. 22, 1291. https:\/\/www.mdpi.com\/1422-0067\/22\/3\/1291 (2021).","DOI":"10.3390\/ijms22031291"},{"key":"58401_CR13","doi-asserted-by":"publisher","unstructured":"Wilson, S. E. Corneal myofibroblasts and fibrosis. Exp. Eye Res. 201, 108272. https:\/\/doi.org\/10.1016\/j.exer.2020.108272 (2020).","DOI":"10.1016\/j.exer.2020.108272"},{"key":"58401_CR14","doi-asserted-by":"publisher","unstructured":"Liu, S., Yang, W., Li, Y. & Sun, C. Fetal bovine serum, an important factor affecting the reproducibility of cell experiments. Sci. Rep. 13, 2023. https:\/\/doi.org\/10.1038\/s41598-023-29060-7 (1942).","DOI":"10.1038\/s41598-023-29060-7"},{"key":"58401_CR15","doi-asserted-by":"publisher","unstructured":"Delabie, W. et al. Comparison of culture media supplements identifies serum components in self-reported serum-free preparations. Stem Cell. Res. Ther. 16 (1), 454. https:\/\/doi.org\/10.1186\/s13287-025-04561-6 (2025).","DOI":"10.1186\/s13287-025-04561-6"},{"key":"58401_CR16","doi-asserted-by":"publisher","unstructured":"Lee, D. Y. et al. Analysis of commercial fetal bovine serum (FBS) and its substitutes in the development of cultured meat. Food Res. Int. 174, 113617. https:\/\/doi.org\/10.1016\/j.foodres.2023.113617 (2023).","DOI":"10.1016\/j.foodres.2023.113617"},{"key":"58401_CR17","doi-asserted-by":"publisher","unstructured":"Stival, A. C. S., da Silva, A. C. G. & Valadares, M. C. Qualitative and quantitative evaluation of Fetal Bovine Serum composition: toward ethical and best quality in vitro science. NAM J. https:\/\/doi.org\/10.1016\/j.namjnl.2025.100047 (2025).","DOI":"10.1016\/j.namjnl.2025.100047"},{"key":"58401_CR18","doi-asserted-by":"publisher","unstructured":"Aswad, H., Jalabert, A. & Rome, S. Depleting extracellular vesicles from fetal bovine serum alters proliferation and differentiation of skeletal muscle cells in vitro.BMC Biotechnol. 16, 32. https:\/\/doi.org\/10.1186\/s12896-016-0262-0 (2016).","DOI":"10.1186\/s12896-016-0262-0"},{"key":"58401_CR19","doi-asserted-by":"publisher","unstructured":"van der Valk, J. et al. Fetal Bovine Serum (FBS): past - present - future. ALTEX 35, 99\u2013118. https:\/\/doi.org\/10.14573\/altex.1705101 (2018).","DOI":"10.14573\/altex.1705101"},{"key":"58401_CR20","doi-asserted-by":"publisher","unstructured":"Gstraunthaler, G., Lindl, T. & van der Valk, J. A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology 65, 791\u2013793. https:\/\/doi.org\/10.1007\/s10616-013-9633-8 (2013).","DOI":"10.1007\/s10616-013-9633-8"},{"key":"58401_CR21","doi-asserted-by":"publisher","first-page":"1612903","DOI":"10.3389\/ftox.2025.1612903","volume":"7","author":"T Weber","year":"2025","unstructured":"Weber, T. et al. Fetal bovine serum: how to leave it behind in the pursuit of more reliable science. Front. Toxicol. 7, 1612903. https:\/\/doi.org\/10.3389\/ftox.2025.1612903 (2025).","journal-title":"Front. Toxicol."},{"key":"58401_CR22","doi-asserted-by":"publisher","unstructured":"Hemeda, H., Giebel, B. & Wagner, W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells, Cytotherapy 16, 170\u2013180. https:\/\/doi.org\/10.1016\/j.jcyt.2013.11.004 (2014).","DOI":"10.1016\/j.jcyt.2013.11.004"},{"key":"58401_CR23","doi-asserted-by":"publisher","unstructured":"Subbiahanadar Chelladurai, K. et al. Alternative to FBS in animal cell culture - an overview and future perspective. Heliyon 7, e07686. https:\/\/doi.org\/10.1016\/j.heliyon.2021.e07686 (2021).","DOI":"10.1016\/j.heliyon.2021.e07686"},{"key":"58401_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1753-6561-5-S8-O3","volume":"5","author":"L Romagnoli","year":"2011","unstructured":"Romagnoli, L. et al. Cell-based medicinal products and the development of GMP-compliant processes and manufacturing. BMC Proc. 5, 33. https:\/\/doi.org\/10.1186\/1753-6561-5-S8-O3 (2011).","journal-title":"BMC Proc."},{"key":"58401_CR25","doi-asserted-by":"publisher","unstructured":"Burnouf, T., Strunk, D., Koh, M. B. & Schallmoser, K. Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation? Biomaterials 76, 371\u2013387. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.10.065 (2016).","DOI":"10.1016\/j.biomaterials.2015.10.065"},{"key":"58401_CR26","doi-asserted-by":"publisher","unstructured":"Pytlik, R. et al. The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering. Biomaterials 30, 3415\u20133427. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.03.001 (2009).","DOI":"10.1016\/j.biomaterials.2009.03.001"},{"key":"58401_CR27","doi-asserted-by":"publisher","unstructured":"Dos Santos, V. T. et al. Characterization of human AB serum for mesenchymal stromal cell expansion. Transfus. Med. Hemother. 44 (1), 11\u201321. https:\/\/doi.org\/10.1159\/000448196 (2017).","DOI":"10.1159\/000448196"},{"key":"58401_CR28","doi-asserted-by":"publisher","unstructured":"Guiotto, M., Raffoul, W., Hart, A. M., Riehle, M. O. & di Summa, P. G. Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review. J. Transl. Med. 18 (1), 351. https:\/\/doi.org\/10.1186\/s12967-020-02489-4 (2020).","DOI":"10.1186\/s12967-020-02489-4"},{"key":"58401_CR29","doi-asserted-by":"publisher","unstructured":"Psychogios, N. et al. The human serum metabolome. PLoS One 6, e16957. https:\/\/doi.org\/10.1371\/journal.pone.0016957 (2011).","DOI":"10.1371\/journal.pone.0016957"},{"key":"58401_CR30","doi-asserted-by":"publisher","unstructured":"Lange, C. et al. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J. Cell. Physiol. 213 (1), 18\u201326. https:\/\/doi.org\/10.1002\/jcp.21081 (2007).","DOI":"10.1002\/jcp.21081"},{"key":"58401_CR31","doi-asserted-by":"publisher","unstructured":"Doucet, C. et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J. Cell Physiol. 205, 228\u2013236. https:\/\/doi.org\/10.1002\/jcp.20391 (2005).","DOI":"10.1002\/jcp.20391"},{"key":"58401_CR32","doi-asserted-by":"publisher","unstructured":"Han, Y. et al. Mesenchymal stem cells for regenerative medicine. Cells 8, 13. https:\/\/doi.org\/10.3390\/cells8080886 (2019).","DOI":"10.3390\/cells8080886"},{"key":"58401_CR33","doi-asserted-by":"publisher","unstructured":"Neo, S. H. et al. Expansion of human bone marrow-derived mesenchymal stromal cells with enhanced immunomodulatory properties. Stem Cell. Res. Ther. 14 (1), 259. https:\/\/doi.org\/10.1186\/s13287-023-03481-7 (2023).","DOI":"10.1186\/s13287-023-03481-7"},{"key":"58401_CR34","doi-asserted-by":"publisher","unstructured":"Dos Santos, A. et al. Differentiation capacity of human mesenchymal stem cells into keratocyte lineage. Invest. Ophthalmol. Vis. Sci. 60 (8), 3013\u20133023. https:\/\/doi.org\/10.1167\/iovs.19-27008 (2019).","DOI":"10.1167\/iovs.19-27008"},{"key":"58401_CR35","doi-asserted-by":"publisher","unstructured":"Taoum, A. et al. 3D differentiation of bone-marrow derived mesenchymal stromal cells into the keratocyte lineage for corneal bioprinting. Adv. Healthc. Mater. 14 (28), e2405073. https:\/\/doi.org\/10.1002\/adhm.202405073 (2025).","DOI":"10.1002\/adhm.202405073"},{"key":"58401_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.engreg.2021.03.002","volume":"2","author":"Y Piao","year":"2021","unstructured":"Piao, Y. et al. Biomedical applications of gelatin methacryloyl hydrogels. Eng. Regener. 2, 47\u201356. https:\/\/doi.org\/10.1016\/j.engreg.2021.03.002 (2021).","journal-title":"Eng. Regener."},{"issue":"12","key":"58401_CR37","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1039\/d5ma00076a","volume":"6","author":"F Dehli","year":"2025","unstructured":"Dehli, F. et al. Biobased photocrosslinkable gelatin-methacrylate hydrogels promote the growth and phenotype maintenance of human corneal keratocytes. Mater. Adv. 6 (12), 3805\u20133816. https:\/\/doi.org\/10.1039\/d5ma00076a (2025).","journal-title":"Mater. Adv."},{"key":"58401_CR38","doi-asserted-by":"publisher","unstructured":"Nishida, T. Commanding roles of keratocytes in health and disease. Cornea 29, S3\u20136. https:\/\/doi.org\/10.1097\/ICO.0b013e3181f2d578 (2010).","DOI":"10.1097\/ICO.0b013e3181f2d578"},{"key":"58401_CR39","doi-asserted-by":"publisher","unstructured":"Yam, G. H. F., Riau, A. K., Funderburgh, M. L., Mehta, J. S. & Jhanji, V. Keratocyte biology. Exp. Eye Res. 196, 108062. https:\/\/doi.org\/10.1016\/j.exer.2020.108062 (2020).","DOI":"10.1016\/j.exer.2020.108062"},{"key":"58401_CR40","doi-asserted-by":"publisher","unstructured":"van der Valk, J. et al. Optimization of chemically defined cell culture media\u2013replacing fetal bovine serum in mammalian in vitro methods. Toxicol. Vitro. 24 (4), 1053\u20131063. https:\/\/doi.org\/10.1016\/j.tiv.2010.03.016 (2010).","DOI":"10.1016\/j.tiv.2010.03.016"},{"key":"58401_CR41","doi-asserted-by":"publisher","unstructured":"Claassen, C., Southan, A., Grubel, J., Tovar, G. E. M. & Borchers, K. Interactions of methacryloylated gelatin and heparin modulate physico-chemical properties of hydrogels and release of vascular endothelial growth factor. Biomed. Mater. 13 (5), 055008. https:\/\/doi.org\/10.1088\/1748-605X\/aacdb2 (2018).","DOI":"10.1088\/1748-605X\/aacdb2"},{"key":"58401_CR42","doi-asserted-by":"publisher","unstructured":"Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315\u2013317. https:\/\/doi.org\/10.1080\/14653240600855905 (2006).","DOI":"10.1080\/14653240600855905"},{"issue":"1","key":"58401_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1134\/s0022093026010072","volume":"62","author":"IS Kolesnikova","year":"2026","unstructured":"Kolesnikova, I. S. et al. Effect of platelet lysate on mammalian cell proliferation. J. Evol. Biochem. Physiol. 62 (1), 70\u201378. https:\/\/doi.org\/10.1134\/s0022093026010072 (2026).","journal-title":"J. Evol. Biochem. Physiol."},{"key":"58401_CR44","doi-asserted-by":"publisher","unstructured":"Pei, Y., Sherry, D. M. & McDermott, A. M. Thy-1 distinguishes human corneal fibroblasts and myofibroblasts from keratocytes. Exp. Eye Res. 79 (5), 705\u2013712. https:\/\/doi.org\/10.1016\/j.exer.2004.08.002 (2004).","DOI":"10.1016\/j.exer.2004.08.002"},{"key":"58401_CR45","doi-asserted-by":"publisher","unstructured":"Sidney, L. E. & Hopkinson, A. Corneal keratocyte transition to mesenchymal stem cell phenotype and reversal using serum-free medium supplemented with fibroblast growth factor-2, transforming growth factor-beta3 and retinoic acid. J. Tissue Eng. Regen Med. 12 (1), e203\u2013e215. https:\/\/doi.org\/10.1002\/term.2316 (018).","DOI":"10.1002\/term.2316"},{"key":"58401_CR46","doi-asserted-by":"publisher","unstructured":"Guo, X., Sriram, S., Tran, J. A., Hutcheon, A. E. K. & Zieske, J. D. Inhibition of human corneal myofibroblast formation. Invest. Ophthalmol. Vis. Sci. 59 (8), 3511\u20133520. https:\/\/doi.org\/10.1167\/iovs.18-24239 2018).","DOI":"10.1167\/iovs.18-24239"},{"key":"58401_CR47","doi-asserted-by":"publisher","unstructured":"Seidelmann, N. et al. Human platelet lysate as a replacement for fetal bovine serum in human corneal stromal keratocyte and fibroblast culture. J. Cell. Mol. Med. 25 (20), 9647\u20139659. https:\/\/doi.org\/10.1111\/jcmm.16912 (2021).","DOI":"10.1111\/jcmm.16912"},{"issue":"1","key":"58401_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000448196","volume":"44","author":"VTM dos Santos","year":"2016","unstructured":"dos Santos, V. T. M. et al. Characterization of human AB serum for mesenchymal stromal cell expansion. Transfus. Med. Hemotherapy. 44 (1), 11\u201321. https:\/\/doi.org\/10.1159\/000448196 (2016).","journal-title":"Transfus. Med. Hemotherapy"},{"key":"58401_CR49","doi-asserted-by":"publisher","unstructured":"Fernandez-Rebollo, E. et al. Human platelet lysate versus fetal calf serum: these supplements do not select for different mesenchymal stromal cells. Sci. Rep. 7, 5132. https:\/\/doi.org\/10.1038\/s41598-017-05207-1 (2017).","DOI":"10.1038\/s41598-017-05207-1"},{"key":"58401_CR50","doi-asserted-by":"publisher","unstructured":"Schallmoser, K., Henschler, R., Gabriel, C., Koh, M. B. C. & Burnouf, T. Production and quality requirements of human platelet lysate: a position statement from the working party on cellular therapies of the international society of blood transfusion. Trends Biotechnol. 38 (1), 13\u201323. https:\/\/doi.org\/10.1016\/j.tibtech.2019.06.002 (2020).","DOI":"10.1016\/j.tibtech.2019.06.002"},{"key":"58401_CR51","doi-asserted-by":"publisher","unstructured":"Bieback, K., Fernandez-Munoz, B., Pati, S. & Schafer, R. Gaps in the knowledge of human platelet lysate as a cell culture supplement for cell therapy: a joint publication from the AABB and the International Society for Cell & Gene Therapy. Cytotherapy 21, 911\u2013924. https:\/\/doi.org\/10.1016\/j.jcyt.2019.06.006 (2019).","DOI":"10.1016\/j.jcyt.2019.06.006"},{"key":"58401_CR52","doi-asserted-by":"publisher","unstructured":"Jian, Y., Dehli, F., Wisbar, M., Taoum, A. & Duarte Campos, D. In situbioprinting: bioprinting methods, bioinks, cell sources & advanced bioprinting strategies. Biofabrication 18, 1. https:\/\/doi.org\/10.1088\/1758-5090\/ae3cc3 (2026).","DOI":"10.1088\/1758-5090\/ae3cc3"},{"key":"58401_CR53","doi-asserted-by":"publisher","unstructured":"Klotz, B. J., Gawlitta, D., Rosenberg, A., Malda, J. & Melchels, F. P. W. Gelatin-methacryloyl hydrogels: towards biofabrication-based tissue repair. Trends Biotechnol. 34 (5), 394\u2013407. https:\/\/doi.org\/10.1016\/j.tibtech.2016.01.002 (2016).","DOI":"10.1016\/j.tibtech.2016.01.002"},{"key":"58401_CR54","doi-asserted-by":"publisher","unstructured":"Sharifi, S., Sharifi, H., Akbari, A. & Chodosh, J. Systematic optimization of visible light-induced crosslinking conditions of gelatin methacryloyl (GelMA). Sci. Rep. 11 (1), 23276. https:\/\/doi.org\/10.1038\/s41598-021-02830-x (2021).","DOI":"10.1038\/s41598-021-02830-x"},{"key":"58401_CR55","doi-asserted-by":"publisher","unstructured":"Liao, Y. et al. A bioequivalent cornea cross-linking method using photo-initiators LAP and visible light. Mater. Today Bio 34, 102110. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102110 (2025).","DOI":"10.1016\/j.mtbio.2025.102110"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58401-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:06:20Z","timestamp":1781730380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58401"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58401-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18874"}}